- Health Canada DPD: ONE-ALPHA (CHEPLAPHARM ARZNEIMITTEL GMBH, DIN 00474525) · product monograph (PDF)
- Health Canada DPD: SANDOZ ALFACALCIDOL (SANDOZ CANADA INCORPORATED, DIN 02533316) · product monograph (PDF)
- Spain CIMA (Spanish): search for “alfacalcidol” (external search; text not reproduced)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Contraindications
- Hypercalcemia
- Hypersensitivity
Dosing: Adult
- Renal bone disease, hyperparathyroidism, hypoparathyroidism, rickets and osteomalacia (adults): Start 1 microgram once daily (0.5 microgram in older adults); maintenance usually 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH
- Hemodialysis, intermittent: 0.5 to 2 micrograms after each dialysis session, adjusted in 0.25 to 0.5 microgram steps
Dosing: Altered kidney function
Alfacalcidol (1-alpha-hydroxyvitamin D3) is converted in the liver to calcitriol, bypassing the kidney's 1-alpha-hydroxylation step, so it is a kidney-indicated drug (uremic bone disease, secondary hyperparathyroidism). The Irish label titrates the dose to calcium, phosphate and parathyroid hormone (PTH) and gives an after-dialysis intermittent regimen. Hypercalcemia is the main risk. It has no US FDA label.
Kidney function measure: Not renally cleared; dose titrated to calcium, phosphate and PTH. Bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- No kidney dose adjustment: alfacalcidol is designed for impaired renal 1-alpha-hydroxylation. Start 1 microgram/day (0.5 microgram in older adults); usual maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate, PTH and alkaline phosphatase (SmPC). Add a phosphate binder in renal bone disease.
- CrCl 30–59 mL/min
- KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
- CrCl 15–29 mL/min
- KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
- CrCl <15 mL/min (not on dialysis)
- KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
- Hemodialysis (intermittent)
- Daily dosing as above, or intermittent dosing after each dialysis (2 to 3 times weekly): start 0.5 to 2 micrograms, adjust by 0.25 to 0.5 microgram steps by PTH, calcium and phosphate. Converting daily to intermittent: daily dose × 7/3 (three times weekly) or × 7/2 (twice weekly), rounded to 0.25 microgram (SmPC).
- Peritoneal dialysis
- Daily dosing titrated to calcium, phosphate and PTH (SmPC).
- CRRT
- No CRRT-specific guidance; usually held in acute illness. Specialist input.
- Dialyzable? Not stated. In overdose, hemodialysis with low-calcium dialysate can treat hypercalcemia (SmPC 4.9).
- Monitoring Serum calcium and phosphate regularly; PTH, alkaline phosphatase and calcium × phosphate product as indicated. If hypercalcemia occurs, stop until calcium normalizes (about 1 week), then restart at half the dose. Hypercalcemia can worsen kidney function and cause nephrocalcinosis (SmPC 4.4). In CKD, check calcium and phosphate often during titration and after each dose change, and PTH at the intervals in the KDIGO CKD-MBD guideline; prefer non-calcium phosphate binders if calcium is high-normal.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Dose by weight and titrated to calcium, phosphate and PTH (SmPC).
- eGFR 30–59
- Dose by weight and titrated to calcium, phosphate and PTH (SmPC).
- eGFR 15–29
- Dose by weight and titrated to calcium, phosphate and PTH (SmPC).
- eGFR <15 (not on dialysis)
- Dose by weight and titrated to calcium, phosphate and PTH (SmPC).
- Hemodialysis (intermittent)
- No pediatric intermittent-dosing guidance; titrate to calcium and PTH. Specialist.
- Peritoneal dialysis
- Weight-based daily dosing titrated to calcium and PTH.
- CRRT
- No data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (May 2021). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Children and neonates (SmPC).
- Usual dose
- Over 20 kg: 1 microgram/day. Under 20 kg: 0.05 microgram/kg/day. Neonates and premature infants: 0.05 to 0.1 microgram/kg/day (up to 2 micrograms/kg/day in severe neonatal hypocalcemia) (SmPC).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Softgel capsule: 0.5 mcg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Alfacalcidol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Medi-Alpha 0.25Alfacalcidol | 250 ng Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Mega Lifesciences Public Company LimitedThailand | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc. | DR-XY39121 | Mar 2, 2031 | |
Philvita Alfa DAlfacalcidol | 0.5 mcg Softgel CapsulePVC/Alu blister pack x 10's (Box of 100's) | Rx | Phil Inter Pharma Co., Ltd.Vietnam | Bliss Pharma Distribution and Consultancy Corp. | DR-XY40881 | May 16, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other vitamin D preparations or analogues | Avoid | Hypercalcemia. | Avoid combining analogues. |
| Thiazides, calcium-containing products | Adjust or monitor | Hypercalcemia. | Monitor calcium. |
| Digoxin | Adjust or monitor | Arrhythmia if hypercalcemia occurs. | Monitor calcium; caution. |
| Magnesium-containing antacids | Adjust or monitor | Hypermagnesemia. | Avoid in kidney failure where possible. |
| Aluminum-containing products | Adjust or monitor | Higher aluminum levels. | Monitor for aluminum toxicity. |
| Enzyme-inducing anticonvulsants (phenytoin, carbamazepine, barbiturates) | Minor | Faster alfacalcidol metabolism. | Larger doses may be needed. |
| Cholestyramine | Minor | Lower absorption. | Give alfacalcidol 1 hour before or 4 to 6 hours after. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Hypercalcemia, hypercalciuria
- Hyperphosphatemia
- Abdominal discomfort
- Rash, pruritus
Serious
- Severe hypercalcemia
- Acute kidney injury, nephrolithiasis, nephrocalcinosis
- Vascular and soft-tissue calcification
Monitoring parameters
- Serum calcium and phosphate regularly; PTH, alkaline phosphatase and calcium × phosphate product as indicated. If hypercalcemia occurs, stop until calcium normalizes (about 1 week), then restart at half the dose. Hypercalcemia can worsen kidney function and cause nephrocalcinosis (SmPC 4.4). In CKD, check calcium and phosphate often during titration and after each dose change, and PTH at the intervals in the KDIGO CKD-MBD guideline; prefer non-calcium phosphate binders if calcium is high-normal. Kidney
- Calcium and phosphate regularly
- PTH and alkaline phosphatase
- Calcium × phosphate product
Pharmacokinetics
Key PK parameters
| Time to peak | Calcitriol peaks 8 to 12 hours after a dose |
|---|---|
| Half-life | Calcitriol about 35 hours |
| Metabolism (CYP, transporters) | 25-hydroxylated in the liver to calcitriol (1,25-dihydroxyvitamin D3) |
| Active metabolites | Calcitriol |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). One-Alpha 0.25 microgram soft capsules SmPC (PA2239/017/002) [HPRA (Ireland) product information, May 2021; no US FDA label]. https://assets.hpra.ie/products/Human/13960/Licence_PA2239-017-002_28052021151451.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- CHEPLAPHARM Arzneimittel GmbH. (2021). One-Alpha 0.25 microgram soft capsules (alfacalcidol) [Summary of product characteristics, licence PA2239/017/002; text revised May 2021]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/13960/Licence_PA2239-017-002_28052021151451.pdf
- Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., Moe, S. M., Shroff, R., Tonelli, M. A., Toussaint, N. D., Vervloet, M. G., & Leonard, M. B. (2017). Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) guideline update: What's changed and why it matters. Kidney International, 92(1), 26–36. https://doi.org/10.1016/j.kint.2017.04.006
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
